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Abstract 
Blastocystis hominis and Endolimax nana exist as two separate parasitic organisms; 
however co-infection with the two individual parasites has been well documented. 
Although often symptomatic in immunocompromised individuals, the pathogenicity of 
the organisms in immunocompetent subjects causing gastrointestinal symptoms has 
been debated, with studies revealing mixed results. Clinically, both B. hominis and E. nana 
infection may result in acute or chronic diarrhea, generalized abdominal pain, nausea, 
vomiting, flatulence and anorexia. We report the case of a 24-year-old immunocompetent 
male presenting with chronic diarrhea and abdominal pain secondary to B. hominis and 
E. nana treated with metronidazole, resulting in symptom resolution and eradication of the 
organisms. Our case illustrates that clinicians should be cognizant of both B. hominis and 
E. nana infection as a cause of chronic diarrhea in an immunocompetent host. Such 
awareness will aid in a timely diagnosis and possible parasitic eradication with resolution 
of gastrointestinal symptoms. 
 
Introduction 
Blastocystis hominis and Endolimax nana are two intestinal parasitic organisms 
that are distributed worldwide with a higher prevalence in tropical and sub-tropical 
climates. Co-infection of these organisms occurs due to their identical mode of 
transmissions, via the fecal-oral route and ingestion of cysts from contaminated water  
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supplies. When ingested, these parasites are commonly reported to be pathogenic in 
immunocompromised individuals, resulting in a milieu of gastrointestinal symptoms 
ranging from mild abdominal pain and flatulence to acute and sometimes chronic 
diarrhea. Despite these organisms’ role in immunocompromised individuals, their 
pathogenicity in immunocompetent individuals is debatable. Diagnosis of the infectious 
agents is made through stool analysis for ova and parasites. Stool specimens are 
examined for cysts by light microscopy after wet mount preparation, trichrome staining 
and formal-ethyl acetate concentration. We report the case of a recently emigrated 
24-year-old male with chronic diarrhea and abdominal pain secondary to B. hominis 
and E. nana, which resolved with parasitic eradication.  
Case Report 
A 24-year-old male who had recently emigrated from El Salvador presented to the clinic with 
complaints of diffuse abdominal pain and diarrhea for the past 6 weeks. He stated that 6 weeks before 
he had begun noticing diffuse, intermittent abdominal pain that was neither relieved nor aggravated 
by any factors. He described the pain as sharp, and stated that episodes would last approximately 
30 min before resolving by themselves. The patient also stated that for nearly 6 weeks, he had been 
having diarrhea, described as 4–5 loose bowel movements daily. He described the diarrhea as 
large-volume, watery, brown stool, which was non-bloody and void of mucus. He denied any 
unintentional weight loss, nausea, vomiting, intermittent constipation, melena, hematemesis, fevers 
or chills. He also denied any recent travel, sick contacts, changes in dietary habits or any recent 
antibiotic use.  
Past medical and surgical history was unremarkable and family history was not significant, 
including the absence of any malignancy or gastrointestinal disorders. He denied the use of any 
tobacco, alcohol or recreational drugs and stated that he was taking no medications at home. He 
stated that he had never had sexual intercourse before and had never received blood transfusions. 
As part of a routine physical and laboratory examination prior to arrival in the United States 
8 weeks earlier, purified protein derivative testing for tuberculosis and screening for human 
immunodeficiency virus had yielded negative results.  
Physical examination revealed a well-built male in mild distress. Examination of the oral mucosa 
was significant for dry mucosal membranes, with no evidence of oral thrush. Abdominal examination 
was remarkable for mild epigastric tenderness without guarding, rebound tenderness or rigidity. 
Digital rectal examination was performed without evidence of overt bleeding. Laboratory evaluation 
including a complete blood count, comprehensive metabolic panel, thyroid stimulating hormone and 
coagulation panel were all within normal limits. Fecal occult blood testing was negative, as was 
testing for Helicobacter pylori stool antigen. Stool cultures were negative for bacterial or viral 
pathogens. Stool examination for ova and parasites performed was positive for B. hominis (fig. 1) 
and E. nana (fig. 2) species. 
Given the diarrheal symptoms along with the apparent co-infection of B. hominis and E. nana, the 
patient was started on a course of 500 mg of metronidazole to be taken 3 times a day for 10 days. The 
patient was advised to return to the clinic in 14 days to re-evaluate symptomatology after a 10-day 
course of antibiotics directed towards B. hominis and E. nana eradication. When the patient returned 
to the clinic, he stated complete resolution of both abdominal pain and diarrhea. Physical examination 
performed was unremarkable and the patient appeared comfortable and in no acute distress. A repeat 
stool examination for ova and parasites was negative for B. hominis and E. nana in three separate stool 
samples, and the patient now continues to be symptom-free.   
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Discussion 
B. hominis is single-celled protozoan intestinal parasite that is a member of the 
Blastocystis genus of Stramenopiles, which includes water molds, algae and diatoms. 
The B. hominis cysts are usually round, measuring 6–40 μm, with a large vacuole 
and absence of an internal nuclear structure; however the vacuole itself is bordered 
by numerous nuclei. The organism reproduces through binary fission and pseudopod 
extension and retraction [1]. B. hominis itself has an equal geographic distribution 
worldwide, however its clinical relevance in contributing to gastrointestinal 
symptomatology appears more in underdeveloped nations in tropical or sub-tropical 
climates [2]. The clinical prevalence in underdeveloped nations may be secondary to 
the organism’s mode of transmission, as fecal-oral, water-borne (contaminated water) 
and food-borne (raw foods) vectors have been reported as the most likely sources. 
Pathogenicity occurs with ingestion of mature cysts leading to lysis of gut epithelium 
and secretion of diarrheagenic toxins [3].  
E. nana is an amoeboid organism found in the intestines of humans and other 
animals. Cysts of E. nana are usually oval or round, measuring 5–10 μm in diameter [1]. 
Their properties include hyaline pseudopodia, which result in sluggish motility of the 
organisms. The cytoplasm of the organism is vacuolated and may or may not contain 
bacteria. E. nana is also known to have a worldwide distribution, with predominance in 
tropical regions and an equivalent mode of transmission as B. hominis. Gastrointestinal 
symptoms from E. nana occur from mature cyst ingestion and subsequent irritation of 
the intestinal mucosal crypts leading to fibrosis [2]. 
Although both B. hominis and E. nana exist as two separate parasitic organisms, 
co-infection with the two individual parasites has been well documented. One 
postulated reason for the high rates of this parasitic co-infection includes their identical 
mode of transmission. Poorly sanitized living conditions and unhygienic food and water 
sources allow one to be vulnerable to polyparasitic infiltration [4]. In a study by Lu 
and Sung [5], an immigrant population in northeastern Taiwan had stool studies 
performed to obtain evidence of B. hominis infiltration, along with the possibility of 
polyparasitic infection. The investigation concluded that over 20% of stool samples 
obtained were positive for polyparasitism, with nearly 79% of those individuals having 
evidence of B. hominis and a subsequent parasite transmitted via the fecal-oral mode 
such as E. nana. The study suggested that due to lower socioeconomic status and poor 
hygiene standards, these intestinal parasites had high rates of co-infection. Another 
suggested mechanism for polyparasitism includes intestinal susceptibility that occurs 
when the intestinal lumen is initially infested. Initial mucosal irritation and 
inflammation from parasitic infiltration may allow other parasitic organisms to 
infiltrate the gastrointestinal tract [2, 3]. Finally, it is thought that the incidence of 
polyparasitic infection may be directly proportional to the immune status of the 
affected individual.  
B. hominis and E. nana have been reported as common pathogens in cases of acute 
or chronic diarrhea in immunocompromised patients [1, 2, 6]. For several years, 
B. hominis and E. nana have been reported to cause gastrointestinal symptoms in 
patients infected with the human immunodeficiency virus and those with acquired 
immunodeficiency syndrome. The severity of gastrointestinal symptoms in these 
individuals varied, as those patients with a severely compromised host immune status  
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appeared to have persistent and unremitting symptoms [7]. Patients with chronic 
renal insufficiency on hemodialysis are known to be immunocompromised, thus these 
patients appear to be susceptible to B. hominis and E. nana infection. In a study by Kulik 
et al. [2], patients with chronic renal insufficiency on hemodialysis with associated 
diarrhea were studied for parasitic prevalence. On stool samples, B. hominis and E. nana 
organisms were found in 20 and 16%, respectively, with co-infection occurring in 21% 
of the patients sampled. The study concluded that these organisms were pathogenic in 
uremic patients with diarrhea if other causes of diarrhea had been ruled out, 
emphasizing a need for parasitic eradication in these individuals. 
In underdeveloped countries, B. hominis and E. nana have been reported in high 
prevalence as causes of acute diarrhea in children. This is likely due to immature 
immune systems along with poor sanitized conditions. In a study by Graczyk et al. [3], 
stool samples from school-aged children with diarrhea in Zambia were taken for 
testing. The samples were negative for bacterial and viral enteropathogens, however 
they were positive for B. hominis and E. nana (53.8 and 63.4%, respectively) and 
co-infection with both parasites in 43%. The study concluded a significant association 
between the parasites and diarrhea. Similar rates of infection were also reported in 
studies from Argentina, Chile, Kuwait, Thailand and Venezuela [8–12]. Although the 
pathogenicity of B. hominis and E. nana has been well reported in the literature 
regarding immunocompromised hosts, its clinical relevance in immunocompetent 
individuals is not clear.  
In healthy individuals, the prevalence of B. hominis and E. nana is 10–15% 
worldwide, with higher rates in underdeveloped countries [7]. The pathogenicity of the 
organisms causing gastrointestinal symptoms in immunocompetent subjects has been 
debated, with studies revealing mixed results. In a 2-year study of enteropathogens 
associated with acute diarrhea, Oyofo et al. [4] concluded that B. hominis and E. nana 
were indeed the cause of gastrointestinal symptomatology in a significant portion of 
immunocompetent individuals. To the contrary, Leder et al. [13] presented B. hominis 
positivity on stool samples to be equivalent in symptomatic and asymptomatic patients 
who were both immunocompetent and immunosuppressed, suggesting that the 
organisms may not be pathogenic, regardless of host immune status. Various case 
reports have argued the pathogenicity of these parasites as causes of gastrointestinal 
symptoms, and consensus guidelines regarding the approach to immunocompetent 
patients with or without symptoms have yet to be established [14, 15]. 
Clinically, both B. hominis and E. nana infection may result in acute or chronic 
diarrhea, generalized abdominal pain, nausea, vomiting, flatulence and anorexia. 
Complications from chronic diarrhea can be serious and sometimes fatal and may 
include dehydration, malnutrition and metabolic acidosis. Diagnosis of both B. hominis 
and E. nana infection can be made via stool sample testing for ova and parasites. Stool 
specimens are examined through light microscopy by direct wet mount, trichrome 
stains and formal-ethyl acetate concentration. Infectivity is classified by identification 
and quantification of B. hominis cysts and E. nana cysts and trophozoites present in 
stool specimens [1, 16–18]. Enzyme-linked immunosorbent assay for serum antibodies 
and polymerase chain reaction techniques can also be used for diagnosis, however 
availability is limited and appears to not be cost-effective.   
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The Centers for Disease Control and Prevention (CDC) has listed B. hominis as a 
‘common’ intestinal parasite found throughout the world that may or may not induce 
gastrointestinal symptoms. The CDC recommends routine testing of stool ova and 
parasites in anyone with acute or chronic diarrhea, and suggests treatment of 
B. hominis if other causes of diarrhea have been ruled out. Unlike B. hominis, E. nana is 
labeled as non-pathogenic intestinal protozoa by the CDC in both immunocompetent 
and immunosuppressed individuals, not warranting treatment if the parasite is isolated 
in stool analysis. Despite the recommendations of the CDC, few case reports have 
concluded that treatment and eradication of E. nana in patients with diarrhea resulted 
in complete resolution of symptoms. It should be mentioned however that in a patient 
with co-infection of both B. hominis and E. nana, treatment aimed at eradication of both 
parasites is not specified [19, 20]. 
Metronidazole has been shown to be an effective treatment option for both 
B. hominis and E. nana infection. Case reports have suggested the efficacy of 
metronidazole in both clearance of organisms from stool samples and resolution of 
symptoms [17, 20]. Nitazoxanide and trimethoprim-sulfamethoxazole have also been 
reported to be effective in cases of metronidazole resistance [6, 16, 20]. Clearance of 
the organisms is determined with three separate negative stool samples. Patients with 
resolution of symptoms but persistent positive tests are known as asymptomatic 
carriers of the organisms, a title which currently appears to bear no clinical 
significance. 
Conclusion 
B. hominis and E. nana are intestinal parasites that have been shown to cause 
gastrointestinal symptoms in both immunocompetent and immunocompromised hosts. 
Although the pathogenicity of both parasites is debatable, our case illustrates that one 
should be cognizant of potential eradication of such organisms if found in the setting of 
chronic diarrhea. By the same token, we believe clinicians should be aware that these 
organisms may be non-pathogenic in immunocompetent individuals, and other causes 
of chronic diarrhea should be investigated if symptoms persist despite parasitic 
eradication after treatment. 
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Fig. 1. Stool specimen, wet mount preparation (high-power field, 40× magnification). Note the 
B. hominis cyst with a large vacuole and the absence of internal nuclear structure (arrows). 
 
 
 
Fig. 2. Stool specimen, wet mount preparation (high-power field, 40× magnification). Note the 
presence of the multinucleated cyst of E. nana measuring 5–6 μm (arrows). 
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